Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Free Cash Flow (2019 - 2025)

Pulmonx (LUNG) has disclosed Free Cash Flow for 7 consecutive years, with -$8.5 million as the latest value for Q3 2025.

  • Quarterly Free Cash Flow fell 17.31% to -$8.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$33.6 million through Sep 2025, up 1.76% year-over-year, with the annual reading at -$32.9 million for FY2024, 14.24% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$8.5 million at Pulmonx, down from -$4.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$4.0 million in Q2 2025, with the low at -$15.5 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$9.9 million, with a median of -$9.6 million recorded in 2022.
  • The sharpest move saw Free Cash Flow crashed 69.29% in 2021, then rose 29.9% in 2024.
  • Over 5 years, Free Cash Flow stood at -$13.3 million in 2021, then grew by 27.17% to -$9.7 million in 2022, then rose by 5.24% to -$9.2 million in 2023, then rose by 14.09% to -$7.9 million in 2024, then fell by 7.98% to -$8.5 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$8.5 million, -$4.0 million, and -$13.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.